Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P21359: Variant p.Leu844Phe

Neurofibromin
Gene: NF1
Feedback?
Variant information Variant position: help 844 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Leucine (L) to Phenylalanine (F) at position 844 (L844F, p.Leu844Phe). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (L) to large size and aromatic (F) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In NF1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 844 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 2839 The length of the canonical sequence.
Location on the sequence: help GSIDLSDTDSLQEWINMTGF L CALGGVCLQQRSNSGLATYS The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSNSGLATYS

Mouse                         GSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSSSGLATYS

Rat                           GSIDLSDTDSLQEWINMTGFLCALGGVCLQQRSSSGLATYS
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 2 – 2839 Neurofibromin
Chain 2 – 1305 Neurofibromin truncated
Modified residue 864 – 864 Phosphoserine
Alternative sequence 552 – 2839 Missing. In isoform 3.
Alternative sequence 594 – 2839 Missing. In isoform 5.
Helix 832 – 846



Literature citations
NF1 gene analysis focused on CpG-rich exons in a cohort of 93 patients with neurofibromatosis type 1.
Boulandet E.G.; Pantel J.; Cazeneuve C.; Van Gijn M.; Vidaud D.; Lemay S.; Martin J.; Zeller J.; Revuz J.; Goossens M.; Amselem S.; Wolkenstein P.;
Hum. Mutat. 16:274-275(2000)
Cited for: VARIANT NF1 PHE-844; Automated comparative sequence analysis identifies mutations in 89% of NF1 patients and confirms a mutation cluster in exons 11-17 distinct from the GAP related domain.
Mattocks C.; Baralle D.; Tarpey P.; ffrench-Constant C.; Bobrow M.; Whittaker J.;
J. Med. Genet. 41:E48-E48(2004)
Cited for: VARIANTS NF1 ARG-31; PRO-145; ARG-324; VAL-337; CYS-489; PRO-532; ARG-574; ARG-629; PHE-665; PHE-844; PRO-844; MET-991 DEL; VAL-1073; ARG-1196; GLY-1276; GLN-1276; GLU-1430; GLU-1459 DEL AND GLY-1489; VARIANTS GLU-176 AND CYS-873;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.